Sareum Holdings Raises £3.2M and Restores AIM Trading Status

Key Facts

1Sareum Holdings raised approximately £3.2 million through a subscription of new ordinary shares.

2The new funding will be used to support the company's lead drug programme, SDC-1801.

3The company announced the restoration of its share trading on the London Stock Exchange's AIM market.

Sareum Holdings raised approximately £3.2 million through a subscription of new ordinary shares, Benzinga reported. The company announced the restoration of its share trading on the London Stock Exchange's AIM market following a temporary suspension. The new funding is earmarked to support the company's lead drug programme, SDC-1801.

The capital injection serves as a critical milestone for the biotech firm's clinical development pipeline. Shares of SAR.L resumed trading on October 26, 2026, as the company secured the necessary liquidity to advance its research. The funding focus remains on the development of kinase inhibitors for autoimmune diseases and cancer applications.